Economic Comparison of Oral Triptans for Management of Acute Migraine: Implications for Managed CareByC.E. Reeder, RPh, PhD,Sharm Steadman, PharmD, BCPS, FASHP,Scott D. Goldfarb, PharmD, MBAFebruary 1st 2002
Almotriptan Versus Sumatriptan in Migraine Treatment: Direct Medical Costs of Managing Adverse Chest SymptomsByLisa K. Mannix, MD,James U. Adelman, MD, FACP,Scott D. Goldfarb, PharmD, MBA,Randal L. Von Seggern, PharmD, BCPS,Chris M. Kozma, PhDFebruary 1st 2002
Cost Savings in Migraine Associated with Less Chest Pain on New Triptan TherapyByJoseph T. Wang, MS,Charles E. Barr, MD,Yas Torigoe, PhD,Elaine Wang, BS,Clayton R. Rowland, PhD,Scott D. Goldfarb, PharmD, MBAFebruary 1st 2002
